Follow on Google News News By Tag * Pharmaceuticals * Therapeutics * Cancer Therapy * Cancer Intervention * Cancer Eradication * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | A US Patent of ITE for Cancer Intervention and Eradication Was Issued to AhR Pharmaceuticals, IncAhR Pharmaceuticals Announces the Issuance of Its First Own Patent by United States Patent and Trademark Office (USPTO)
ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor. Once binding to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community as well have demonstrated ITE’s potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems. “We are glad to see the recognition by the USPTO of our innovation and invention to the benefit of patients around the world,” said Dr. Jiasheng (Jason) Song, the Chief Scientific Officer of AhR Pharmaceuticals. “We have been prosecuting pending patents around the world and will continue the filing of patent applications from our important inventions to protect our intellectual property and build values for our investors,” continued Dr. Song. “More importantly, by doing all of these, it will ultimately enable us to do tremendously good things to benefit our patients around the globe.” The patent (US 8,604,067 B2) is entitled “ITE for Cancer Intervention and Eradication” AhR Pharmaceuticals, Inc., with licensed ITE technologies as its foundational intellectual property from Wisconsin Alumni Research Foundation (WARF, the intellectual property manager of University of Wisconsin-Madison, a world-renowned research university), is devoted to the development of natural hormone ITE into an efficacious and sustainable but low side-effect therapeutic agent in intervention and possible eradication of cancer, obesity, and disorders due to imbalanced actions of immune systems. For more information on AhR Pharmaceuticals, Inc., its technologies, and research activities, please visit http://www.ahrpharma.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|